BNOX has 36-month beta value of 0.13. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BNOX is 8.15M, and currently, short sellers hold a 2.33% ratio of that float. The average trading volume of BNOX on November 20, 2024 was 9.26M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BNOX) stock’s latest price update
The stock of Bionomics Ltd. ADR (NASDAQ: BNOX) has decreased by -5.18 when compared to last closing price of 0.30. Despite this, the company has experienced a -3.72% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-08 that ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provides an update to the proposed re-domiciliation of Bionomics to the United States by way of scheme of arrangement between Bionomics and its Shareholders (“Scheme”) as announced on 1 October 2024.
BNOX’s Market Performance
Bionomics Ltd. ADR (BNOX) has seen a -3.72% fall in stock performance for the week, with a -7.57% decline in the past month and a -55.25% plunge in the past quarter. The volatility ratio for the week is 15.32%, and the volatility levels for the past 30 days are at 24.01% for BNOX. The simple moving average for the past 20 days is -2.97% for BNOX’s stock, with a -62.42% simple moving average for the past 200 days.
Analysts’ Opinion of BNOX
Many brokerage firms have already submitted their reports for BNOX stocks, with H.C. Wainwright repeating the rating for BNOX by listing it as a “Buy.” The predicted price for BNOX in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on September 28, 2023 of the previous year 2023.
Maxim Group, on the other hand, stated in their research note that they expect to see BNOX reach a price target of $10, previously predicting the price at $7. The rating they have provided for BNOX stocks is “Buy” according to the report published on September 28th, 2023.
H.C. Wainwright gave a rating of “Buy” to BNOX, setting the target price at $54 in the report published on January 10th of the previous year.
BNOX Trading at -25.39% from the 50-Day Moving Average
After a stumble in the market that brought BNOX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.13% of loss for the given period.
Volatility was left at 24.01%, however, over the last 30 days, the volatility rate increased by 15.32%, as shares sank -4.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.11% lower at present.
During the last 5 trading sessions, BNOX fell by -3.69%, which changed the moving average for the period of 200-days by -69.35% in comparison to the 20-day moving average, which settled at $0.2905. In addition, Bionomics Ltd. ADR saw -80.95% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNOX
Current profitability levels for the company are sitting at:
- -160.75 for the present operating margin
- -55.25 for the gross margin
The net margin for Bionomics Ltd. ADR stands at -145.58. The total capital return value is set at -1.15. Equity return is now at value -59.91, with -42.49 for asset returns.
Based on Bionomics Ltd. ADR (BNOX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -65.53. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -2340.37.
Currently, EBITDA for the company is -9.84 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of -13.67. The receivables turnover for the company is 1.26for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.30.
Conclusion
To put it simply, Bionomics Ltd. ADR (BNOX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
